ABBV has been in the news 308% more than usual
May 15, 2025, 6:31 AM
7.64%
What does ABBV do
AbbVie is a North Chicago-based biopharmaceutical company that develops and sells medicines across various therapeutic areas, employing 50,000 staff since its IPO in January 2013. Key products include Humira, Botox, and NX-13 for ulcerative colitis.
ABBV has been in the news recently: AbbVie Inc. (ABBV) has seen its stock price at $188.93 after a slight drop, but it has increased by 6.84% this month and 15.33% over the past year. Additionally, AbbVie is collaborating with ADARx Pharmaceuticals to develop siRNA therapies, and the FDA has granted accelerated approval for AbbVie's Emrelis for treating advanced non-small cell lung cancer.
📡️ Health Care
In The News
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
